

**Date: 29.12.2015**

To,  
Listing Department,  
**Bombay Stock Exchange Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

Fax : 022-22723121/2041/ 1072

**Kind Attn. Mr. Rakesh Parekh**

**Ref: Scrip Code - 532908 Scrip ID - SHARONBIO**

**Sub: Submission of Financial Results under Clause 41 of the Listing Agreement.**

Dear Sir,

Received your mail dated 28.12.2015 we hereby send you the financial results for the quarter ended 30<sup>th</sup> September, 2015 after rectifying the face value of the equity shares to Rs. 2/- per equity shares. Enclosed herewith is the un-audited Financial Results for the Quarter ended **30<sup>th</sup> September, 2015.**

Thanking You.

Yours Faithfully,  
**For Sharon Bio-Medicine Limited**



**(Savita Gowda)**  
**Managing Director**  
**DIN: 00042957**



**UNAUDITED STANDALONE FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER  
ENDED SEPTEMBER 30, 2015.**

(Rs. In Lacs)

SR. NO.	PARTICULARS	Quarter ended & year to the date			30/06/2015 (Audited)
		As on 30/09/2015	As on 30/06/2015	As on 30/09/2014	
1	Net Sales / Income from Operations	11,299.48	14,195.82	32,491.62	83,395.46
	Total Income	11,299.48	14,195.82	32,491.62	83,395.46
2	<b>Total Expenditure</b>				
	a) (Increase)/Decrease in Stock in Trade	(553.31)	(1,803.85)	(1,849.85)	2,102.68
	b) Consumption of Materials	9,550.67	13,329.67	23,104.69	69,903.89
	c) Purchases of Trading Goods	355.66	510.21	5,529.04	8,843.17
	d) Employees Cost	549.10	362.71	660.28	1,982.87
	e) Depreciation	499.57	553.70	302.42	1,925.93
	f) Other Expenditure	964.73	1,270.99	1,192.34	3,991.89
	<b>Total</b>	<b>11,366.42</b>	<b>14,223.43</b>	<b>28,938.92</b>	<b>88,750.43</b>
3	Profit from Operations before Exchange Rate Difference, Other Income, Interest & Exceptional Items ( 1 - 2 )	(66.94)	(27.61)	3,552.70	(5,354.97)
4	Other Income	71.50	119.26	106.28	263.21
5	Profit from Operations before Interest & Exceptional Items ( 3 + 4 )	4.56	91.65	3,658.98	(5,091.76)
6	Interest	1,672.05	4,975.35	1,396.79	9,364.48
7	Profit after Interest but before Exception items (5-6)	(1,667.49)	(4,883.70)	2,262.19	(14,456.24)
8	Exception Items	5,911.38	3,825.24	(139.01)	7,663.80
9	Profit (+)/Loss(-) from Ordinary Activities before tax (7+8)	(7,578.87)	(8,708.94)	2,123.18	(22,120.04)
10	Tax Expenses	-	(466.36)	312.68	(466.36)
11	Net Profit before ordinary activities ( 8 - 9 )	(7,578.87)	(8,242.58)	1,810.50	(22,586.40)
12	Extra Ordinary Items (Net of Tax)	-	-	-	-
13	Net Profit after Taxes ( 10 - 11 )	(7,578.87)	(8,242.58)	1,810.50	(22,586.40)
14	Paid up Equity Share Capital (Face value of Rs. 2/- each)	2,378.71	2,378.71	2,111.38	2,378.71
15	Reserves excluding Revaluation Reserves	-	-	33,327.88	9,338.00
16	<b>Earning Per Shares (Before Extra Ordinary Item)</b>				
	i) Basic	(7.18)	(7.81)	1.71	(21.39)
	ii) Diluted E. P. S	(4.92)	(5.35)	1.18	(14.67)
17	<b>Earning Per Shares (After Extra Ordinary Item)</b>				
	i) Basic	(7.18)	(7.81)	1.71	(21.39)
	ii) Diluted E. P. S	(4.92)	(5.35)	1.18	(14.67)

**Part -II**

SR. NO.	PARTICULARS	Quarter ended & Year to the date			30/06/2015 (Audited)
		As on 30/09/2015	As on 30/06/2015	As on 30/09/2014	
(A)	Aggregate of Public Shareholdings				
	No. of Shares	46,067,652	46,067,652	42,017,020	46,067,652
	Percentage of Shareholdings	38.73%	38.73%	39.80%	38.73%
18	Promoters & promoter group Shareholding				
	<b>a) Pledged / Encumbered</b>				
	- Number of Shares	4,632,000	4,632,000	5,000,000	4,632,000
	- Percentage of Shares	6.36%	6.36%	7.87%	6.36%
	(as a % of the total shareholding of promoter & promoter group)				
	- Percentage of Shares	3.89%	3.89%	4.74%	3.89%
	(as a % of the total share capital of the Company)				
	<b>b) Non-encumbered</b>				
	- Number of Shares	68,236,048	68,236,048	58,551,980	68,236,048
	- Percentage of Shares	93.64%	93.64%	92.13%	93.64%
	(as a % of the total shareholding of promoter & promoter group)				
	- Percentage of Shares	57.38%	57.38%	55.46%	57.38%
	(as a % of the total share capital of the Company)				

**Notes:-**

- The above results for the quarter ended September 30, 2015 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in its meeting held on November 10, 2015
- The "Limited Review" required under clause 41 of listing agreement has been done by statutory auditors of the Company.
- The Company has provided for Foreign Exchange (Loss)/Gains under Exception Items due to exchange differences arising during the periods on foreign currency contracts and borrowings including Foreign Currency Convertible Bonds and interest for the current quarter.
- Previous years figures have been regrouped and recast wherever necessary.
- Information on investor complaints for the quarter ended September 30, 2015 (in nos.)

Sr. No	Opening Balance of Complaints	Received during the Quarter	Disposed Off during the Quarter	Closing Balance
1	NIL	3	3	NIL

By order of the Board  
For Sharon Bio-Medicine Ltd.  
SD/-

Place : Mumbai.  
Date : 10.11.2015

Savita Gowda  
Managing Director.

**Office Add. :** Plot No: 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West) Mumbai - 400 053  
Tel. : 91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com  
CIN NO. L24110MH1989PLC052251

www.sharonbio.com

*Caring for relationships*